Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 4

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 4
---
 use and will not be returned to investors. We do not have any arrangements
to place the funds received from the sale of the Units in the Offering in an escrow, trust or similar account.

In addition, we are registering of up to an aggregate
of 37,625,790 shares (the “Shares”) of Common Stock, to be offered for resale, from time to time, by selling stockholders
listed on page Alt-2 of the Resale Prospectus (the “Selling Stockholders”), (the “Resale Offering”). The Shares
in the Resale Offering include (i) 31,253,525 shares of Common Stock of the Company (including 14,479,442 Exchange Shares, as defined
below); (ii) up to 4,925,000 shares of Common Stock issuable upon exercise of common stock purchase warrants issued to certain Selling
Stockholders at a per share exercise price of $0.80 and (iii) up to 1,447,265 shares issuable upon exercise of common stock purchase warrants
issued to certain Selling Stockholders at a per share exercise price of $2.40 (collectively, the “Investor Warrants”). We
are registering the Shares on behalf of the Selling Stockholders, to be offered and sold by them from time to time and will not receive
any proceeds from such sales of Common Stock, if any, by any Selling Stockholders, except for funds to be received by the Company from
the exercise of Investor Warrants by the Selling Stockholders, if and when such Investor Warrants are exercised for cash.

The Resale Offering will commence immediately
upon effectiveness of the registration statement and we anticipate that the Resale Offering will be concurrently conducted when the Primary
Offering of the units is still ongoing. Until our Common Stock is quoted on the OTCQX or the OTCQB marketplace of OTC Market or until
the shares of our Common Stock are listed on a national securities exchange, the Selling Stockholders, or their respective transferees,
pledgees, données or other successors-in-interest, may sell their Shares pursuant to this Prospectus at a fixed price per share
of $1.00. The concurrent Resale Offering at a fixed price of $1.00 per share may adversely affect our ability to raise capital in the
primary offering as the fixed resale price of $1.00 per share can be deemed by prospective investors as more attractive than the $3.20
price per unit